The p97 AAA (ATPase associated with diverse cellular activities), also called VCP (valosin-containing protein), is an important therapeutic target for cancer and neurodegenerative diseases. p97 forms a hexamer composed of two AAA domains (D1 and D2) that form two stacked rings, and an N-terminal domain that binds numerous cofactor proteins. The interplay between the three domains in p97 is complex, and a deeper biochemical understanding is needed in order to design selective p97 inhibitors as therapeutic agents. It is clear that the D2 ATPase domain hydrolyzes ATP in vitro, but whether D1 contributes to ATPase activity is controversial. Here, we use Walker A and B mutants to demonstrate that D1 is capable of hydrolyzing ATP, and show for the first time that nucleotide binding in the D2 domain increases the catalytic efficiency (k cat /K m ) of D1 ATP hydrolysis 280-fold, by increasing k cat 7-fold and decreasing K m about 40-fold. We further show that an ND1 construct lacking D2 but including the linker between D1 and D2 is catalytically active, resolving a conflict in the literature. Applying enzymatic observations to small-molecule inhibitors, we show that four p97 inhibitors (DBeQ, ML240, ML241, and NMS-873) have differential responses to Walker A and B mutations, to disease-causing IBMPFD mutations, and to the presence of the N-domain binding cofactor protein p47. These differential effects provide the first evidence that p97 cofactors and disease mutations can alter p97 inhibitor potency and suggest the possibility of developing context-dependent inhibitors of p97.
Introduction
The highly conserved and abundant p97 protein belongs to the type II AAA ATPase enzyme family and converts chemical energy from ATP hydrolysis into mechanical energy to unfold proteins or disassemble protein complexes. p97 plays a critical role in cellular processes such as Golgi membrane reassembly (1), membrane transport (2,3), degradation of proteins by the ubiquitin-proteasome system (UPS) (4, 5) , regulation of myofibril assembly (6) , cell division (7) , and protein aggregation (8) (9) (10) . Because p97 functions in many protein homeostatic regulatory processes, it is a potential therapeutic target for cancer and neurodegenerative diseases (11) (12) (13) .
Each monomer of p97 ATPase is composed of three domains (the N, D1 ATPase, and D2 ATPase domains) joined by linker regions. D1 and D2 each form a hexameric ring, which stack to form a cylindrical structure, as revealed by X-ray crystallography (14, 15) . Although it is clear that the D2 domain hydrolyzes ATP in vitro, the level of D1-specific ATPase activity varies among different reports (16) (17) (18) . Furthermore, genetic studies in yeast reporting D1 ATPase activity as an essential function are controversial. For example, some mutants that inhibit ATP hydrolysis in the D1 domain affect growth (17) , whereas others do not (19) .
However, a consistent observation is that the nucleotide-binding state of D1 is tightly controlled (15, 18) .
Thus, it is important to clarify the role of the D1 domain in vitro, providing hypotheses that can then be tested in cells.
Adjacent to the D1 domain is the N domain, which functions as a protein-protein interaction site that binds p97 cofactors (20, 21) . By recruiting cofactor proteins, the N domain links the mechanochemical ATPase activity of p97 to many substrate proteins, accounting in part for the broad range of cellular p97 functions. For example, cofactor p47 is required for p97-mediated membrane fusion (22) , by mediating binding of p97 to syntaxin 5 during the reassembly of Golgi stacks at the end of mitosis (23) . Binding of p47 to the N-terminus alters the structure and function of p97 by significantly reducing the diameter of the p97 ring (22) and inhibiting ATPase activity (24) . Hence, p47 supports communication between the N, D1 and D2 domains of p97.
There are several additional lines of evidence for conformational crosstalk among the three domains
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4 of p97. Conformational changes occur during the ATPase cycle, including rotation of the D1 and D2 rings with respect to each other, changes in the hexameric ring diameter, and positioning of the N-domain (25) (26) (27) (28) (29) .
Additionally, pathogenic mutations in the N and D1 domains alter nucleotide binding to the D1 domain and
ATPase activity in the D2 domain (29) (30) (31) . Defining interactions between the D1 and D2 domains could provide opportunities for developing small-molecule inhibitors with diverse mechanisms of inhibition and perhaps diverse cellular effects.
In an effort to better understand the mechanistic and cellular functions of p97, a few potent and specific small molecule inhibitors of p97 ATPase activity have been identified via high-throughput screening, followed by chemical optimization (32) (33) (34) (35) In this study, we enzymatically characterized a set of p97 constructs and mutations to elucidate the effect of small-molecule p97 inhibitors on D1 and D2 domain ATPase activities. We first clarified the in vitro activity of the D1 domain. We found that an ND1-linker truncation is a robust, catalytically competent ATPase whose activity is similar to that of the D1 domain in full-length p97. Interestingly, D1 showed
ATPase activity in the full-length protein only when the D2 domain was capable of binding nucleotides.
Using our enzymatically characterized set of p97 proteins, we addressed the domain specificity of four potent p97 inhibitors on wild type (WT) p97. We then evaluated whether inhibition was sensitive to pathogenic mutations in the ND1 domain or to the presence of bound p47, a p97 binding protein. DBeQ and NMS-873 inhibited both ATPase domains, whereas ML240 and ML241 were specific for D2. In addition, inhibition of
D2 by ML240 and ML241 was altered by a pathogenic mutation in ND1 and upon p47 binding, indicating domain communication within p97. Together, our results provide the framework for developing domain, cofactor-complex, and pathway specific inhibitors (32) , with the ultimate goal of validating p97 as a potential therapeutic target.
Results

The Human p97 D1 Domain is a Competent ATPase
To resolve the controversy over whether the isolated D1 domain can hydrolyze ATP in vitro, we prepared two truncated constructs: ND1 (residues 1-458) without the D1-D2 linker region, and ND1L (1-480), which included the linker region (Fig. 1A) . ND1 was used previously to conclude that D1 was inactive (16) , whereas ND1L has been used in crystallography studies (31) and was recently reported to be catalytically active (29) . Specific activities with 600 M ATP at room temperature for human and mouse p97 were 5.20.3 and 5.10.2 nmol Pi/min/nmol p97, respectively. We found that the ATPase activity of ND1 was 1.4% of the WT level, whereas ND1L had 79% of the WT activity (at 600 uM ATP; Fig. 1B ).
Thus, ND1L was 56-fold more active than ND1. As a comparison to ND1L, we also prepared a truncation containing the D1-D2 linker region plus the D2 domain (LD2; amino acids 461-806). LD2 existed in dynamic multimer-monomer equilibrium (Figs. S1), and thus it was not surprising that its ATPase activity was only 4% of WT values (Fig. 1B) .
To address the difference in activities between ND1 and ND1L, we evaluated their stabilities by differential scanning fluorimetry (DSF; Figs. 1C and D) and nucleotide binding by surface plasmon resonance (SPR; Figs. 2A and B) . Thermal stability studies showed that addition of the linker strongly stabilized ND1 by 13 o C, to a temperature that approaches the first melting transition of full-length p97.
Additionally, ND1 showed multiple melting transitions, whereas ND1L gave a single, highly cooperative melting curve. The increased thermal stability and single-state melting curve suggested that ND1L formed a more stable protein than ND1. To determine whether ND1 bound weakly to nucleotides, leading to low catalytic activity, we monitored binding of nucleotides to ND1 and ND1L by SPR at 20 o C, well below the melting temperature for ND1. Both ND1 and ND1L bound to ATP, ATPS, or ADP with similar binding
affinities and kinetics (within 2-fold) (Fig. S2) . Hence, the linker region had only a small effect on nucleotide-binding affinity, which did not account for the 56-fold increase in ATPase activity. Rather, we concluded that the linker region rendered the D1 domain a competent ATP hydrolase mainly by substantially increasing its thermal stability. We cannot rule out that the linker also favorably altered the conformational dynamics of the protein.
By directly comparing the two constructs that were used in the previous studies, we identified the source of the conflicting results on D1 activity. We demonstrated that ND1L can hydrolyze ATP, which is in a good agreement with the recent report by Tang and coworkers (29) . In contrast, ND1 cannot hydrolyze ATP, which is consistent with the earlier report by Song and coworkers (16) .
Nucleotide Binding and Enzyme Kinetic Analysis of Walker A and B Mutants
We next directly compared the nucleotide binding affinities and activity of ND1L to full-length WT (Fig. 3A , black font indicates the active domain in each protein). We included 0.01% Triton X-100 in our standard reaction buffer and observed a 1.7 fold increase in ATPase activity for WT p97 upon addition of Triton X-100 (Fig. 3A) . In general, the increase in ATPase activity by Triton X-100 was greater for the D1-active Walker B mutant (D2-E578Q) compared to the D2-active Walker B mutant (D1-E305Q) (Fig. 3A ).
These activity data prompted us to measure steady-state kinetic constants (k cat , K m , and k cat /K m ), in order to understand the enzymology of D1 ATPase activity in the context of full-length p97 and to evaluate the crosstalk between the D1 and D2 domains (Table S3 and . D1-E305Q also showed a slightly higher k cat /K m than WT. Taken with D2-E578Q, the data suggested a cross-inhibitory effect on the activity of the D1 and D2 domains. These observations were consistent with the negative cooperativity between the D1 and D2 rings shown for mouse p97 (28) and with the recent demonstration that the presence of D2 inhibited D1 activity (29) . Finally, it is noteworthy that ND1L gave the same kinetic constants as D2-E578Q (Table S3 and Fig. 3C ). Thus, ND1L
can serve as an accurate kinetic model of the D1 domain in the full-length p97.
It is noteworthy that adding detergent (Triton X-100) to the assay buffer was critical for observing robust ND1L activity (Fig. 3C) . Triton X-100 increased k cat 4.7-fold, and had no effect on K m . This result suggested that detergent facilitated catalysis, perhaps by aiding the release of prebound ADP from the hexamer (18, 29) . It was also likely that detergent prevented protein aggregation and reduced protein binding to the surface of the plastic assay plates. We have included 0.01% Triton X-100 in our standard reaction buffer (32, 34) and detergents like Triton X-100 and Tween-20 are frequently added when testing smallmolecule inhibitors to prevent compounds from forming colloids that can cause non-specific enzyme inhibition (39) .
ATP-Competitive p97 Inhibitors, ML240 and ML241 are Selective for the D2 domain
We previously identified three potent, ATP-competitive p97 inhibitors (DBeQ, ML240, and ML241; (Table S4 ) (33, 35) . To investigate whether these four p97 compounds inhibit the ATPase activity of D1, D2, or both domains, IC 50 values were determined for WT p97 and five variants in the presence of 200 M or 875 M ATP. Lower potencies were observed for inhibition of WT p97 (roughly 2 to 5-fold increases in IC 50 ; Fig. 4 and Tables S4 and S5 ).
The ATP competitive inhibitors were sensitive to Walker A and B mutations in both domains. There was a 2.7-to 10-fold increase in IC 50 for D1-E305Q (Walker B mutant in the D1 domain) for DBeQ, ML240, and ML241 (Figs. 4 B-D) . These increases in IC 50 can be partly explained by the 2.4-fold decrease in K m for D1-E305Q, because ATP competitive inhibitors are sensitive to the levels of ATP binding (Fig. 3E) . In contrast to the smaller effects found for the D1 D1-E305Q mutant, ML240 was inactive toward D2 mutants D2-E578Q and D2-K524A, and toward ND1L. ML241 was also inactive towards D2-K524A and ND1L, and showed 147-fold weaker inhibition for D2-E578Q. Thus, both ML240 and ML241 were D2 selective inhibitors (Figs. 4 C and D). DBeQ was less selective, showing 8 to 10-fold weaker inhibition of D2-E578Q, D2-K524A, and ND1L (Fig. 4B) . The "D2 specific" inhibitors were nevertheless sensitive to changes in D1.
For example, the D1 D1-K251A mutation increased the IC 50 for ML240 and ML241 by 27-fold with 200 M ATP and ML240 can not inhibit D1 D1-K251A with 875 M ATP, suggesting that the architecture of the D2 active site was changed significantly due to the mutation and/or due to the absence of nucleotide binding to
D1. This result was consistent with our kinetic analysis of D1-K251A (Fig. 3B) , which also showed strong effects of this mutation on the activity of the D2 domain.
The allosteric inhibitor NMS-873 sensed mutations in the D2 domain, but was insensitive to D1 mutations (Tables S4 and S5 , Fig. 4E ). In agreement with the published data for Walker A mutants, NMS-873 inhibited D1-K251A and WT p97 similarly, but could not bind and inhibit D2-K524A (35).
Unexpectedly, NMS-873 inhibited D2-E578Q (IC 50 1.0 M, or 25-fold higher than for WT p97, Fig. 4E ),
suggesting that maintaining D2 in the ATP-bound state allowed NMS-873 to bind and prevent D1 from hydrolyzing ATP. In addition to the proposed mechanism, whereby NMS-873 prevented ADP release from D2, our D2-E578Q data suggested that NMS-873 locked p97 into a conformation that may have also prevented ADP release from D1. The ATP-binding sites in D1 and D2 are similar for DBeQ binding, because the IC 50 values for D1-E305Q, D1-K251A, D2-E578Q, D2-K524A, and the isolated ND1L are almost identical at higher concentrations of ATP (Table S5) . Therefore, DBeQ inhibits both D1 and D2 ATPase activities similarly. However, ML240 and ML241 behave quite differently. They are much more sensitive to Walker A and B mutations and cannot inhibit D2-E578Q, D2-K524A, and ND1L as potently as seen for D1-E305Q. Thus, they are more selective for inhibiting D2 ATPase activity. Even though NMS-873 does not bind to ATP binding sties, its ability to bind to p97 and inhibit D1 ATPase is diminished for the D2-K524A mutant (35) . However, when D1 and D2 can both bind nucleotides (as in D2-E578Q), NMS-873 inhibits D1
ATP hydrolysis, but 25-fold less potent as compared to D1-E305Q p97. In summary, the four inhibitors fall into three classes: NMS-873, which binds at the D1-D2 interface, seems to inhibit ATPase activity from both D1 and D2 domains; the ATP-competitive inhibitors DBeQ can inhibit both D1 and D2 ATPase activity; and ML240 and ML241 are selective against the D2 domain.
Taken together, the D1 ATPase activity is more difficult to block by p97 inhibitors (Figs. 4 B to E, D2-E578Q). This is consistent with results of our steady state kinetic analysis of D2-E578Q, the mutant with the lowest Km for ATP (Figs. 3B, C, and E) and tighter nucleotide binding to D1 (Table S2 and 
IBMPFD/ALS Mutations and p47 Cofactor Binding Affect Potency of the D2-selective p97 Inhibitors
Mutations at the ND1 interface of p97 cause IBMPFD/ALS (40,41), a devastating degenerative disorder that has no known treatment. Therefore, p97 inhibitors that can correct the increased ATPase activity of mutants to WT levels might be useful for exploration in animal models, as a possible starting point for research on treatment approaches.
To begin to investigate this opportunity, we prepared a series of IBMPFD p97 mutants and tested the activity of ML240 and ML241. We first confirmed a prior report (38) that the elevated ATPase activity from mutants such as A232E arose from turnover in D2 (Fig. 6A) . As expected, when D1 activity was knocked out by D1-E305Q, D2 activity was increased by A232E, whereas A232E had no affect on D1-mediated ATPase activity (D2-E578Q). We then determined IC 50 values for the D2-selective inhibitors, ML240 and ML241, against eight mutants that cause disease (Fig. 6B) . Interestingly, some mutants were less sensitive to the
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p97. This result demonstrated that the conformation at the ND1 interface altered binding of inhibitors to the D2 ATP site. Our data suggest that it may be possible to develop a mutant selective inhibitor. Selective inhibition of the mutant subunit may reduce the pool of active p97 mutants (or hexamers containing mutants)
within cells, so that cells use predominantly WT hexamers. However, additional work will be required to develop mutant-selective inhibitors.
Inhibitor potency was clearly affected by IBMPFD/ALS mutations and by the nucleotide binding state of the D1 domain of p97, even though these mutations are distal to the small-molecule binding site in the D2 domain. By extension, we hypothesized that cofactor binding to p97 might also be critical for p97
inhibitor potency. Therefore, we evaluated inhibitor potency for p97-p47 complexes at four concentrations of p47 (Table S6 and Fig. 7 ). All concentrations of p47 increased the IC 50 of DBeQ 4-to 6-fold (Fig. 7A ).
More dramatically, p47 trimer concentrations greater than 16.7 nM increased IC 50 values of ML240 and ML241 more than 49-fold and 37-fold, respectively (Figs. 7B and C). In contrast, only a minor 2-fold effect was detected for the allosteric inhibitor NMS-873 (Fig. 7D ). This result provided the first demonstration that a major p97 cofactor, p47, can influence the potency of ATP-competitive p97 inhibitors.
Discussion
Our interest is to understand the function of the D1 and D2 p97 ATPase domains, through kinetic analysis of mutants, and use of small molecule inhibitors. The impetus to evaluate effects of p97 inhibitors came from work on the D1 inhibitor, Eeyarestatin I (27) , and the N-domain inhibitor, Xanthohumo1 (28).
Neither of these compounds blocks full-length p97 ATPase activity, but they inhibit some p97-dependent cellular activities. The results suggest that modifying activity of either the N or D1 domain by small molecules may alter different p97 functions in cells. Moreover, the human disorder known as IBMPFD/ALS is associated with dominantly inherited, missense mutations in the N, ND1 linker, and D1 domains (that cause high p97 ATPase activity), but not by mutations in D2 (29, 30) .
The AAA ATPase p97 is a dynamic molecular machine that consists of two ATPase domains, D1
and D2, which function to drive the molecular remodeling of protein substrates. We first did a systematic comparison of D1 and D2 ATPase activity to resolve the controversy on whether D1 is an active ATPase.
With the active ND1L mutant and Walker A and B mutants for both D1 and D2, we carried out steady-state kinetic analyses and dose-dependent titrations with 4 p97 inhibitors against these mutants.
Our steady-state kinetic analyses provide molecular insights into the roles of both ATPase domains, and also indicate that nucleotide binding and p97 inhibitors modulate each domain interdependently. We
show that the ND1L domain is a catalytically competent ATPase, resolving a debate in the literature. Tang
and coworkers (29) demonstrated ATPase activity in an ND1L construct (Fig. 1A) , whereas two other labs published that ND1 was inactive (16, 18) . Moreover, our results provide a plausible explanation for the conflicting reports on whether D1 is an active ATPase. We show that the D1-D2 linker region (residues 459-480) dramatically improves thermal stability (Fig. 1D) . However, both ND1 and ND1L are capable of binding nucleotides when the temperature is below the melting temperature ( Figs. 2A and B) . These data are consistent with X-ray crystallography studies that reveal identical active-site structural arrangements for ND1, ND1L, and the ND1 domain in the full-length enzyme (14, 15, 31, 42) . One possible explanation for the 56-fold increase in activity in the ND1L construct is that the linker region positions a water molecule into a catalytically competent orientation to hydrolyze ATP.
In this study, we provide quantitative analysis of kinetic constants for the D1 and D2 ATPase domains of human p97, by using point mutations at the conserved Walker A and B positions of D1 and D2 (16, 17, 36) Our results showed that ATP hydrolysis within the D1 domain of a full-length p97 protein containing a Walker B mutation in D2 (D2-E578Q) exhibited Michaelis-Menten behavior almost identical to that for ND1L (Fig. 3C , Table S3 ). Consistent with the enzymology, isolated ND1L was found to bind nucleotides with similar affinities as the D1 domain in full-length p97 (Figs. 2 and S2) . Furthermore, the K m of D1 (D2-E578Q) for ATP was ~20-fold less than the D2 value (D1-E305Q) (Fig. 3E) , consistent with the 10-fold tighter nucleotide binding to D1 than to D2 (Table S2 ) (18) . Although the D1 maximal velocity was about 3.5 times lower than for WT p97 (Figs. 3C and D) , the k cat /K m for D1 is actually 14-fold higher than the WT value, indicating that D1 is a catalytically competent ATPase within full-length p97.
Previous studies hinted that intra-and inter-domain communication within the p97 hexamer is important for p97 activity (17, (27) (28) (29) 37) . We found that preventing nucleotide binding in the D2 domain using a Walker A mutant (D2-K524A) drastically impaired both the D1 K m for ATP (~40-fold weaker) and catalytic activity (7-fold lower k cat ), as compared to a D2-E578Q mutant (Fig. 3A) . This striking finding
indicates that nucleotide binding to D2 is required for D1 activity in full-length p97. Hence, domain communication within the p97 hexamer critically controls the capacity of both domains to hydrolyze ATP.
Moreover, the tighter Km for D1 may imply that D1 ATPase activity is more important under stress conditions, when cellular ATP concentration is depleted (45) (46) (47) (48) .
In contrast to our experiments with ND1L, a truncation strategy was not suitable for investigating the catalytic efficiency of the D2 ATPase, because isolated D2 cannot form stable hexamers ( (Table S3 ). Conversely, the Walker A mutation in D1 (D1-K251A) prevented D2 from reaching maximal WT activity, no matter how much ATP was present. Because the K m values are similar for D1-D1-K251A and D1-E305Q (Figs. 3A and D) , we conclude that nucleotide binding to D1 is essential to achieve maximal k cat values for D2 (18, 37) .
Together, our results support the presence of domain communication within the full-length WT p97
ATPase, in which nucleotide binding to one ATPase domain is essential for activity of the other domain.
Further work is needed to decipher the precise roles and the molecular mechanisms of this communication.
In particular, the importance of D1 ATPase activity in cells is controversial (17, 19, 29) , and our enzymatic
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14 studies with mutants pave the way to investigate the cellular role of D1 activity, cooperativity between D1 and D2, and the extent to which p97 cofactors are involved in regulating such communication.
Our results also have implications for the design of p97 inhibitors for use in cancer and neurodegeneration. We have generated a set of tools to develop D1-and D2-domain specific inhibitors, and clearly demonstrated the existence of two types of ATP-competitive inhibitors. DBeQ inhibits both D1 and D2, whereas ML240 and ML241 only inhibit the D2 ATPase domain (Figs. 4 A-C and Tables S4 and S5 ).
Moreover, inhibition by ML240 and ML241 is sensitive to IBMPFD/ALS mutations in p97 (Fig. 6B) ,
suggesting that IBMPFD/ALS-selective inhibitors might be developed via either structure-based drug design or high-throughput screens.
Another significant finding in this study is the roughly 50-fold decrease in ML240 potency in the presence of p47, providing the first evidence that p97 cofactors can affect the potency of ATP-competitive inhibitors (Figs. 7A-C, and Table S6 ). These results favor an interpretation that the p97-p47 complex exists in a conformation that cannot be inhibited by ML240 and ML241 as effectively as by the allosteric inhibitor NMS-873. Indirect evidence suggests that p97 ATP binding sites exist in different conformations in the presence of p47, because p47 dramatically changes the global p97 conformation (21, 22, 50) and lowers the maximal velocity of ATPase activity by 5-fold (24) . Thus, it may be possible to develop complex-specific p97 inhibitors for p47 and other p97 cofactor proteins (51) . It is enticing to consider whether ML240 and ML241 may inhibit a subset of p97 complexes in cells, whereas NMS-873 may be a broad-spectrum inhibitor. Future in vivo studies are needed to compare anti-cancer potencies and general toxicities of distinct classes of p97 inhibitors. Taken together, our results provide a new way to consider domain communication in p97 and the tools to develop D1-or D2-domain selective, complex-specific, and disease-mutant-selective p97 inhibitors.
Materials and Methods
Materials-Plasmids used are listed in Supplemental Table S1 . . A 2-fold decrease for the Walker A mutation of D1 (D1-K251A), a 3-fold increase for the Walker B mutation of D1 (D1-E305Q), a 15-fold decrease for the Walker A mutation of D2 (D2-K524A), and a 14-fold increase for the Walker B mutation of D2 (D2-E578Q) together suggest that D1 is a catalytically competent ATPase, when D2 is able to bind to nucleotides. 
BIOMOL Green ATPase Assay-
[RL] = ((K D + [L] + [R]) -√((K D + [L] + [R]) 2 -4[L][R]))/2(3)A = A f + (A b -A f ) x [RL](4
